They found that there was no difference in disease recurrence, recurrence free and overall survival between EGFR mutated and EGFR wild-type NSCLC, but there was a higher incidence of distant disease recurrence rate and lower incidence of locoregional recurrence rate for EGFR mutated NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.